...
首页> 外文期刊>Bone marrow transplantation >Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood
【24h】

Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood

机译:在儿童时期血液生物干细胞移植后永久弥漫性脱发

获取原文
获取原文并翻译 | 示例
           

摘要

Permanent alopecia after haematopoietic stem cell transplantation (HSCT) is distressing and few studies have investigated this late effect. The aim of the study was to assess the percentage of patients with alopecia and investigate risk factors for alopecia. Patients who underwent allogeneic HSCT before age 19 years, from January 1990 to January 2013, who were at least 2 years after transplant and in follow-up in our clinic were included. Alopecia was defined as clinically apparent decreased hair density. Possible risk factors considered for alopecia after HSCT included: gender, age, diagnosis, donor type, conditioning regimen: cranial irradiation (TBI/cranial radiotherapy) and/or chemotherapy, which chemotherapeutic agents were used and acute/chronic GvHD. The percentage of permanent alopecia in our cohort was 15.6% (41/263 patients). All patients had diffuse alopecia except for one with alopecia totalis. In multivariate analysis, a conditioning regimen with busulphan and busulphan plus fludarabine (odds ratio (OR) 5.7 (confidence interval (CI): 2.5-12.7) and OR 7.4 (CI: 3.3-16.2), respectively, was the main risk factor and associated with alopecia independent of acute/chronic GvHD. Neither TBI nor other alkylating chemotherapy, including treosulfan, was associated with alopecia. In conclusion, permanent alopecia after HSCT is associated with busulphan and GvHD and occurs in 16% of patients.
机译:血液生成干细胞移植(HSCT)后永久性脱发令人痛苦,少数研究已经调查了这一晚期效果。该研究的目的是评估患有脱发患者的百分比并调查脱发的风险因素。在19年前接受同种异体的HSCT患者,从1990年1月到2013年1月,他们在移植后至少2年和我们诊所的后续行动。脱发被定义为临床上明显下降的头发密度。 HSCT之后脱发的可能危险因素包括:性别,年龄,诊断,供体类型,调理方案:使用颅照射(TBI /颅放射疗法)和/或化疗,使用该化学治疗剂和急性/慢性GVHD。我们的队列中永久性脱发的百分比为15.6%(41/263名患者)。除了用Alopecia Totalis的患者,所有患者均已弥漫血症。在多变量分析中,分别具有伯勒布伦和伯勒仑和氟甲兰的调理方案(OTDS比率(或)5.7(置信区间(CI):2.5-12.7)和或7.4(CI:3.3-16.2)是主要风险因素和与疾病无关的急性/慢性GVHD相关。TBI也没有其他烷基化化学疗法,包括葡萄干,与脱发有关。总之,HSCT后永久性的脱发与伯勒胡麻和GVHD相关,并在16%的患者中发生。

著录项

  • 来源
    《Bone marrow transplantation》 |2017年第7期|共5页
  • 作者单位

    Leiden Univ Willem Alexander Childrens Hosp Med Ctr POB 9600 NL-2300 RC Leiden Netherlands;

    Leiden Univ Willem Alexander Childrens Hosp Med Ctr POB 9600 NL-2300 RC Leiden Netherlands;

    Leiden Univ Dept Internal Med Endocrinol Med Ctr Leiden Netherlands;

    Leiden Univ Willem Alexander Childrens Hosp Med Ctr POB 9600 NL-2300 RC Leiden Netherlands;

    Leiden Univ Dept Med Stat &

    Bioinformat Med Ctr Leiden Netherlands;

    Leiden Univ Dept Dermatol Med Ctr Leiden Netherlands;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号